Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 5 IN PLASTIC CONTAINER versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 5 IN PLASTIC CONTAINER versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
MANNITOL 5% IN PLASTIC CONTAINER vs OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases the osmolarity of the glomerular filtrate, reducing tubular reabsorption of water and solutes. It also draws water from intracellular spaces into the extracellular fluid, reducing cerebral edema and intraocular pressure.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
50-100 g intravenously over 30-60 minutes for initial dose in acute renal failure or cerebral edema; maintenance dose 25-50 g every 6-8 hours based on serum osmolality and urine output.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours (adults with normal renal function); prolonged to 24–48 hours in severe renal impairment.
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Renal: >90% as unchanged drug via glomerular filtration; negligible biliary or fecal elimination.
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic